<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04921982</url>
  </required_header>
  <id_info>
    <org_study_id>35RC18_8852_PROPRADO</org_study_id>
    <nct_id>NCT04921982</nct_id>
  </id_info>
  <brief_title>Efficacy of Traumatic Memory Modification Using Memory Reconsolidation and Propranolol Among Adolescents With PTSD</brief_title>
  <acronym>PROPRADO</acronym>
  <official_title>The Efficacy of Traumatic Memory Modification Using a Memory Reconsolidation Procedure Under Propranolol Among Adolescents With Post-traumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to demonstrate the effectiveness of propranolol in blocking&#xD;
      reconsolidation by reducing PTSD symptoms in the short and long term in adolescents with PTSD&#xD;
      for more than 3 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change on score of PCL-5</measure>
    <time_frame>7 weeks</time_frame>
    <description>Difference on score on the PTSD Checklist for DSM-5 (PCL-5) between inclusion and one week after the end of treatment. PCL-5 is a 20-item self-report measure of the DSM-5 symptoms of PTSD used as a continuous measure. A decrease of 10 points on the PCL is usually considered as a clinically significant improvement. It has been used worldwide and among adolescents (Wang, 2015; Cao, 2017)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Post Traumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Oral administration of Propranolol, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse once a week for six consecutive weeks.</description>
    <arm_group_label>Propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of Placebo, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse, once a week for six consecutive weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Adolescents aged 12 to 18 years;&#xD;
&#xD;
          -  Exposed to a single traumatic event or to events circumscribed in time, including&#xD;
             sexual abuse in the absence of reminders in the environment;&#xD;
&#xD;
          -  Fluent in French;&#xD;
&#xD;
          -  Positive diagnosis of PTSD with the SCID-5;&#xD;
&#xD;
          -  Disorders evolving for at least three months;&#xD;
&#xD;
          -  Heart rate ≥ 55 bpm;&#xD;
&#xD;
          -  Systolic blood pressure ≥ 100 mmHg;&#xD;
&#xD;
          -  Written parental or legal guardian consent;&#xD;
&#xD;
          -  Written agreement by the adolescent;&#xD;
&#xD;
          -  Adolescents affiliated, via their parents, to the French social security body.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Medical condition contraindicating administration of propranolol (COPD, asthma,&#xD;
             cardio-vascular insufficiency, heart failure as second- and third-degree&#xD;
             atrioventricular blocks, Prinzmetal angor, pheochromocytoma, Raynaud disease, history&#xD;
             of an anaphylactic reaction, sinus node disease, hypoglycemia, AV blocks)&#xD;
&#xD;
          -  Known chronic renal or hepatic insufficiency&#xD;
&#xD;
          -  Schizophrenia;&#xD;
&#xD;
          -  Mental retardation;&#xD;
&#xD;
          -  Autism spectrum disorder;&#xD;
&#xD;
          -  Acute severe suicidal ideation&#xD;
&#xD;
          -  Traumatic brain injury (loss of consciousness &gt; 10 minutes);&#xD;
&#xD;
          -  Currently treated for substance or alcohol dependence;&#xD;
&#xD;
          -  Currently treated for Attention Deficit Hyperactivity Disorder;&#xD;
&#xD;
          -  Currently treated with a drug that can interfere with propranolol and that can&#xD;
             represent a danger according to medical advice if it's suspended more than 24 hours.&#xD;
&#xD;
          -  Currently treated with a bradycardic drug;&#xD;
&#xD;
          -  Concurrent psychotropic medication with the exception of cyamemazine (suspended 48&#xD;
             hours before session)&#xD;
&#xD;
          -  Concurrent trauma-focused psychotherapy in progress or stopped less than 1 month ago;&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Current use of &quot;recreative&quot; toxic drugs&#xD;
&#xD;
          -  Concurrent participation to another interventional study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Dayan, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacques Dayan, Pr</last_name>
    <phone>299284321</phone>
    <phone_ext>+33</phone_ext>
    <email>jacques.dayan@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Elise Riquin, Md</last_name>
    </contact>
    <investigator>
      <last_name>Elise Riquin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Lauriane Vuilliez, Md</last_name>
    </contact>
    <investigator>
      <last_name>Lauriane Vuilliez, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Bohars</name>
      <address>
        <city>Bohars</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Guillaume Bronsard</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume Bronsard, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Caroline Dubertret, Pr</last_name>
    </contact>
    <investigator>
      <last_name>Caroline Dubertret, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Le Havre</name>
      <address>
        <city>Le Havre</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Gisele Apter</last_name>
    </contact>
    <investigator>
      <last_name>Gisele Apter, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Bertrand Olliac</last_name>
    </contact>
    <investigator>
      <last_name>Bertrand Olliac, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Olivier Bonnot</last_name>
    </contact>
    <investigator>
      <last_name>Olivier Bonnot, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Ludovic Gicquel</last_name>
    </contact>
    <investigator>
      <last_name>Ludovic Gicquel, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Guillaume Régnier</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jacques Dayan, Pr</last_name>
      <email>jacques.dayan@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques Dayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Priscille GERARDIN</last_name>
    </contact>
    <investigator>
      <last_name>Priscille GERARDIN, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

